Author:
Houweling M.,Abdul U. K.,Brahm C.,Lagerweij T.,Heukelom S.,Koken P. W.,Honeywell R.,Wedekind L. E.,Peters G. J.,Verheul H.,Sminia P.,Noske D.,Wurdinger T.,Westerman B. A.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference33 articles.
1. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM (2009) Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol 11(4):403–413
2. Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ et al (2013) Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res 73(22):6745–6756
3. Brahm CG, Abdul UK, Houweling M, van Linde ME, Lagerweij T, Verheul HMW et al (2020) Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. Neurooncol Adv. 2(1):151
4. Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T et al (2013) Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 19(8):2257–2264
5. Caunt CJ, Sale MJ, Smith PD, Cook SJ (2015) MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer 15(10):577–592
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献